newsfilter
← Latest News
Business Wire·

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in